Key Takeaways
- Margin compression from inventory losses, not structural demand: Gross margins fell QoQ because high-cost raw material inventory booked under FIFO compressed spreads as input prices declined; management expects this drag to largely clear by Q3 FY23.
- Realizations at all-time highs, but pricing power is constrained: The company recorded its highest-ever API and Specialty Chemical realizations, yet price hikes must be gradual to avoid losing orders to competitors holding cheaper inventory.
- Specialty Chemicals ramp-up is behind schedule: The Tarapur Brownfield expansion is running at ~60 of 400 tonnes/month due to scale-up batch issues and delayed equipment; full potential of ₹90–105 Cr is targeted, but management is "not very clear" on how much will be achieved in the next entire year.
- Capex cycle nearing completion, PLI benefit forfeited: Two Greenfield projects (~₹350 Cr) are on track for completion by June 2023, but the company walked away from the PLI scheme for an antiprotozoal project after the government required full committed capex spend.
- What to watch next quarter: Whether high-cost inventory truly exhausts and gross margins begin recovering; the pace of the Tarapur Specialty Chemicals ramp toward the 150-tonne November target; and any stabilization in Metformin and ammonia-linked input prices.
Margin Walk: Inventory Losses and Operating Costs
- FIFO inventory losses drove the gross margin drop: The company piled up raw material inventory at high prices during a volatile 9-month period; as input prices fell, those higher costs flowed through the P&L first, compressing margins even as realizations rose.
- Metformin was a major contributor: DCDA, the key raw material, fell from $4,000–$4,500 to below $3,000 over two quarters; the company held inventory purchased at peak prices and booked significant losses as Metformin selling prices declined in tandem.
- Ammonia-linked products face a structural disadvantage: Ammonia prices are nearly 3x year-ago levels due to the Russia-Ukraine gas shortage; Chinese manufacturers have a raw-material cost advantage on these products, squeezing margins for Indian players with no immediate correction expected.
- Operating costs added pressure: Power and fuel costs rose sharply (coal prices more than doubled), and one-time arrears were paid to employees and labor contractors during the quarter.
- The drag should start clearing in Q3: If input prices remain stable, high-cost inventory should be exhausted by next quarter; improvement should become visible from Q3 onwards, though some impact will carry into the December quarter.
Adhish Patil: "If the volatility goes away, the margins should improve considerably. And going forward, we at least expect around a couple of percent improvement going forward. And they will keep improved scenario becomes stable once all the inventory losses goes away, then the margin should improve. So at the end, we should try to, by the end in Q4, we should try to get EBITDA margins upwards of 15%."
Specialty Chemicals: Delayed Ramp, Large Ambition
- Tarapur Brownfield is running well below capacity: Only ~60 of 400 tonnes/month has been achieved; scale-up batch issues and a few pending equipment deliveries are the bottleneck.
- November target is 150 tonnes/month: Management expects to reach upwards of 150 tonnes in November, aided by a shift from batch to continuous manufacturing with a different Route of Synthesis that should improve consumption norms.
- Full potential is ₹90–105 Cr, but the timeline is uncertain: Management will "try our best to ramp up as soon as possible" and hopes the facility is fully occupied by the end of FY24, but is "not very clear on that, how much we will get for the next entire year."
- Gujarat Greenfield adds a second leg: The chloro-sulphonation project originally planned for Gujarat was instead executed as a 5x Brownfield scale-up in Tarapur; the ultimate plan remains to shift production to a second Greenfield site in Gujarat, which is expected to commission by end-Q1 FY24.
- Diversification beyond chloro-sulphonation is underway: The Gujarat facility will add new specialty chemical products, including contract manufacturing projects with MNCs.
Adhish Patil: "So because it is Specialty Chemical and we have been dealing in this, we will try our best to ramp up as soon as possible. So by the end of next year, hopefully we should be occupying it by the end of next financial year. But how much time it will take, we also are not very clear on that, how much we will get for the next entire year."
Demand and Volume Dynamics
- Domestic demand was subdued for some antibiotics: Volume growth was flat in the domestic market, while export markets saw ~10–11% volume growth.
- Channel inventory is normalizing: Overall pharmaceutical demand was weak in the first two quarters with excess inventory in the channel; inventory is now back to normal, and demand is expected to return to pre-COVID levels as pandemic-related distortions recede.
- Production was maintained despite soft demand: Management chose not to cut production until September, citing good export demand, the usual monsoon-season pickup, and macro uncertainty from the war scenario that made it reluctant to lose output.
- Inventory build-up is now reversing: High production in the last quarter (10% volume growth) converted earlier raw material pile-up into finished goods; the company will now begin scaling back inventory and freeing up working capital.
- Export realizations are higher than domestic: Export prices exceed domestic prices; within exports, the Indian subcontinent and some Southeast Asian markets carry very low prices, while other geographies are much higher, though management could not quantify the differential.
Adhish Patil: "And also because the macro factors where because of this war scenario and others and everything, it was quite unclear. So we did not want to lose on production so that is why we kept on producing."
Capex and Project Updates
- Two Greenfield projects nearing completion: Most of the ~₹350 Cr capex for the Tarapur API Greenfield (derma project) and the Gujarat Greenfield (specialty chemicals and backward integration) will be completed by June 2023.
- Tarapur derma API facility: Expected to start by March 2023 (end of FY23); as of now, no substantial domestic competition, only China.
- Baddi oral oncology plant: ~₹40 Cr of the ₹55 Cr budgeted capex is done; commercial operations expected to commence in March 2023.
- Backward integration plant: Will be completed around May–June 2023; broadly related to antidiabetic and antiprotozoal products; ~60–70% of Gujarat output will be for captive consumption.
- PLI scheme abandoned: The company decided not to proceed with the PLI scheme for an antiprotozoal project after the government required full committed capex spend; committed capex was reduced by almost 50%, and the capacity will still be implemented without the PLI benefit.
- EDQM inspection completed: One Tarapur facility (E22) had a European authority inspection during the current week; described as "quite good," with a report expected in a few days.
Adhish Patil: "So we decided that rather than spending that much, we will spend less upfront and still implement the capacity. But we are doing that project, but we are not going in we are giving up the PLI benefit because we are getting everything in capex."
Gliptins and New Product Pipelines
- Teneligliptin is stabilizing: Production is stable and cost efficiency has improved; the company is working on making intermediates in-house and improving domestic market share, with further gains expected in 1–2 quarters; exports are not yet substantial.
- Vildagliptin is in early export marketing: Sample submissions and validation batches have just begun; meaningful export volumes are expected only after another 2 quarters.
- Bottom-line contribution will lag: Top line from gliptins will start contributing sooner, but the bottom line will take at least 2 quarters to contribute meaningfully.
- U.S. FDA approval being pursued: The company plans to seek U.S. FDA approval for the existing antidiabetic facility, which will be expanded further next year as a dedicated plant.
- Formulation exports are mostly emerging markets: The majority of formulation revenue comes from emerging markets because regulated-market products are either in the pipeline or under approval; most regulated-market pricings have not yet converted to revenue.
Competitive Position and Pricing Power
- Pricing power is real but constrained: Price hikes are being taken and September-quarter selling prices were at maximum levels, but increases must be gradual; if prices are raised suddenly, formulators look for other sources, and competitors holding low-cost inventory can offer lower prices temporarily, causing order loss before the playing field levels.
- Chinese competition is acute on ammonia-linked products: Chinese manufacturers have a raw-material price advantage on ammonia-linked products that Indian players cannot match; the company is approaching the government for anti-dumping duty, but no timeline for an outcome exists.
- Market-share gains in Southeast Asia are offset by the ammonia disadvantage: The company has captured market share from Chinese players in Southeast Asian markets, but the ammonia cost gap affects only Indian players, not Chinese ones, putting the company at a disadvantage despite efficiencies that may be "at par with them or even better."
- DCDA backward integration is not imminent: A peer is pursuing backward integration into DCDA; management notes DCDA manufacturing is tricky and hazardous, and many have tried and not gone ahead in the past; the company may eventually have to go in-house given plans to produce ~3,000 tonnes/month of Metformin.
Adhish Patil: "Even when it comes to Chinese manufacturers, we have captured a lot of their market share in Southeast Asian markets as well but only the few things about ammonia. And that has affected only the Indian players and not the Chinese players. So there, it is slight out of our hands, though even though our efficiencies might be at par with them or even better."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin exit rate | Upwards of 15% | By end of Q4 FY23 |
| High-cost inventory exhaustion | Improvement visible from Q3 onwards | Q3 FY23, assuming stable input prices |
| Tarapur Specialty Chemicals ramp | 150 tonnes/month (out of 400) | November 2022 |
| Tarapur derma API Greenfield | Commence operations | By end of FY23 (March 2023) |
| Baddi oral oncology plant | Commence commercial operations | March 2023 |
| Gujarat Greenfield facility | Commissioning and trials | End of Q1 FY24 (June 2023) |
| Two Greenfield projects capex completion | Most of ~₹350 Cr spent | By June 2023 |
| Vildagliptin meaningful export volumes | Export volumes to pick up | In another 2 quarters |
| Formulation margin recovery | Higher-margin export orders executed | Coming 2 quarters |
| Metformin and DCDA price stabilization | DCDA to stabilize below $3,000; Metformin to stabilize | Already stabilized "more or less" |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Standalone revenue | ₹624.9 cr, +22% YoY |
| Consolidated revenue | ~₹710 cr (per an analyst's math), standalone contributed 88% |
| Formulation segment revenue | ₹82.5 cr, +9% YoY |
| API segment revenue growth | +17% YoY |
| Standalone domestic revenue growth | ~19% YoY |
| Standalone export revenue growth | ~28% YoY |
| Consolidated EBITDA margin (H1 FY23) | 10.8% |
| API segment EBITDA margin | 11.2%, improved from 10% in Q1 FY23 |
| Notional forex loss | ~₹2 cr |
| API volume growth (export) | 11% |
| API volume growth (domestic) | Marginal |
| Formulation segment share of total revenue | ~12% |
| Formulation exports share of formulation revenue | ~44% |
| Standalone domestic revenue share | ~62% |
| Standalone export revenue share | ~38% |
| API therapeutic mix: antibiotic | ~44% of total APIs |
| API therapeutic mix: antidiabetic | ~17% of total APIs |
| API therapeutic mix: antiprotozoal | ~16% of total APIs |
| API therapeutic mix: anti-inflammatory | ~10% of total APIs |
| API therapeutic mix: antifungal | ~8% of total APIs |
| Metformin sales volume | ~1,000 tonnes per month |
| Metformin average capacity | 1,150–1,200 tonnes per month |
| DCDA raw material price | less than $3,000, down from $4,000–$4,500 at beginning of year |
| H1 FY23 capex incurred | ₹77 cr |
| FY23 capex guidance | ₹200–300 cr |
| Baddi formulation capex (total planned) | ₹55 cr, of which ~₹40 cr done |
| Baddi plant full-capacity revenue potential | ₹200 cr |
| Tarapur Specialty Chemicals Brownfield capacity achieved | ~60 out of 400 tonnes per month, expected to reach 150+ in November |
| Tarapur Specialty Chemicals Brownfield full-scale revenue potential | ₹90–105 cr |
| Existing standalone capacities full-scale revenue potential | upwards of ₹3,000 cr |
| Existing formulation capacities full-scale revenue potential | ~₹300 cr |
| Current capacity utilization (API and Specialty Chemicals) | mid-70s% |
| Gujarat Greenfield capex | ~₹150–200 cr |
| Total Greenfield projects capex | ~₹350 cr, expected completion by June 2023 |
| Post-Gujarat backward integration increase | 10–12% of finished sale further backward integrated |
| Ammonia price increase | ~3x versus one year ago |
| Inventory level | ₹500-odd cr |
| Production volume growth | 10% |
| Q4 FY23 EBITDA margin target | upwards of 15% |